Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norditropin Nordilet in idiopathic short stature: 12‑month randomized open-label trial in Korea
2015-002613-30Phase 3
- Sponsor
- Novo Nordisk
- Start
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in Idiopathic Short Stature (ISS) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity after 6 months.
02
Drugs
somatropin
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on 2015-002613-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002613-30.